公开(公告)号：US20160024207A1

公开(公告)日：2016-01-28

申请号：US14774795

申请日：2014-03-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM OF TEXAS SYSTEM

Inventor： Barrett R. HARVEY ,  Kenneth L. PINKSTON ,  Ali AZHDARINA ,  Eva M. SEVICK-MURACA

IPC: C07K16/28 ,  G01N33/574 ,  A61K47/48 ,  C07K16/30 ,  A61K51/10

CPC classification number: C07K16/28 ,  A61K47/6803 ,  A61K47/6865 ,  A61K51/1066 ,  A61K51/1093 ,  C07K16/30 ,  C07K16/3053 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/57434 ,  G01N2333/705

Abstract: Embodiments of the invention provide high affinity recombinant EpCAM-binding antibodies. Methods of using a such antibodies as imaging agents, diagnostics and therapeutics are also provided. Dual-nuclear and fluorescently labeled or singly fluorescently labeled contrast agents promise the advantage of molecularly-guided surgical resection via surgical field near-infrared fluorescence (NIRF) imaging following (in the case of dual labeled agents) nuclear imaging for general localization. Currently, nodal staging of most cancers is performed following lymph node (LN) biopsy and dissection for subsequent pathological examination.

Abstract translation: 本发明的实施方案提供了高亲和力的重组EpCAM结合抗体。 还提供了使用这样的抗体作为成像剂，诊断和治疗剂的方法。 双核和荧光标记或单一荧光标记的造影剂通过外部视野近红外荧光（NIRF）成像（通过双标记试剂）核成像进行一般定位，从而有望分子引导手术切除。 目前，大多数癌症的淋巴结分期在淋巴结（LN）活检和解剖后进行，用于随后的病理检查。